Hello, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of meetings, deadlines, and whatnot has returned. But you knew this would happen, yes? So to cope, we are quaffing cups of stimulation. Feel free to join us. The neurons can also use a little stimulation. Meanwhile, here are some tidbits to help you along. Have a great day and do keep in touch …
An FDA panel will vote Tuesday on whether the label for Jardiance — a diabetes drug from Eli Lilly and Boehringer Ingelheim — should be updated to say it can lower the risk of major cardiovascular events, Reuters says. A study found the drug cut the risk of death from heart attacks and strokes, becoming the first glucose-lowering medicine to show protective results in a large clinical trial.
Six former FDA commissioners believe the agency should be independent, STAT tells us. The FDA is currently part of the US Department of Health and Human Services, but giving it Cabinet-level status or finding another way to authorize more autonomy would be better for public health, the former commissioners said at a weekend meeting, which was also the first time they all supported such a move publicly.
Arizona has run out of execution drugs, including the midazolam sedative implicated in botched lethal injections, according to Reuters, citing a filing filed on Friday in a court case challenging the state’s execution methods. The midazolam, which is made by Akorn Pharmaceuticals, expired on May 31 and the state corrections department it has not been able to replace it. Akorn took steps last year to prevent its drug from being used for executions.
Dr. Reddy’s Laboratories ended a strategic alliance with GlaxoSmithKline for emerging markets outside India and plans to pursue these markets on its own, LiveMint tells us. The revenue-sharing deal was struck in 2009 and was created to develop and market select generic drugs in markets such as Latin America, Africa, the Middle East, and Asia-Pacific, excluding India.
Five drug wholesalers agreed to a $4.2 million settlement in a lawsuit alleging they shipped an excessive number of prescription opioids to West Virginia, the Associated Press tells us. Meanwhile, the West Virginia Board of Pharmacy is developing a system to rank doctors by specialty based on the number of prescriptions they write for painkillers, the Charleston Gazette-Mail writes.
The US Senate might vote next month on its companion to the House’s 21st Century Cures bill, despite procedural obstacles, Bloomberg News reports.
Sanofi and Boehringer Ingelheim agreed on a $25.1 billion asset swap that will bolster the French drug maker’s business selling over-the-counter drugs while exiting animal health, Bloomberg News says.